ADOLFO ALVAREZ
Allopathic & Osteopathic Physicians|Internal Medicine MIAMI BEACH, FL NPI 1639732191
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine FL Acerta Pharma LLC All categories
General Payments — all program years on this page
$580.37
- Category: General Payments
- Program years: PY2021–2024
- Record count: 25
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $227.88 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $227.88 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $64.10 | 3 |
| Actelion Pharmaceuticals US, Inc. | $36.88 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $36.64 | 1 |
| GlaxoSmithKline, LLC. | $33.43 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.14 | 1 |
| ABBVIE INC. | $23.69 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078877890 | Actelion Pharmaceuticals US, Inc. | $36.88 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1103214703 | ABBVIE INC. | $23.69 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1110512176 | AstraZeneca Pharmaceuticals LP | $30.05 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1110513868 | AstraZeneca Pharmaceuticals LP | $16.69 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1110515860 | AstraZeneca Pharmaceuticals LP | $17.36 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1116653155 | GlaxoSmithKline, LLC. | $33.43 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1118092236 | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.14 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1137469718 | Takeda Pharmaceuticals U.S.A., Inc. | $36.64 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.